- HUTCHMED (China) Limited
- 05 September 2025 09:45:15
Source: Sharecast
At WCLC, running from 6 to 9 September, it said presentations would cover updated analyses of savolitinib from the SACHI, SAVANNAH and a phase 3b confirmatory study in non-small cell lung cancer (NSCLC).
Savolitinib, a selective MET tyrosine kinase inhibitor, was being jointly developed with AstraZeneca and commercialised by AstraZeneca.
Studies would include data on biomarker concordance, resistance mechanisms, and efficacy in patients with MET alterations, including those treated with prior immunotherapy.
At CSCO, which takes place from 10 to 14 September, Hutchmed said it would for the first time present clinical results of HMPL-653, a novel CSF-1R inhibitor, from a phase one trial in patients with tenosynovial giant cell tumour.
A series of investigator-initiated studies would also highlight updated data on fruquintinib and surufatinib across colorectal, esophageal, pancreatic, biliary tract and breast cancers, as well as in neuroendocrine tumours.
The company said the breadth of data reflected the progress of its discovery-driven pipeline across multiple cancer indications.
Hutchmed noted that it remained committed to developing targeted therapies and immunotherapies for cancer and immunological diseases, and has already brought three in-house discovered medicines to market in China, with one also approved in the US, Europe and Japan.
At 0920 BST, shares in Hutchmed China were up 6.05% at 228p.
Reporting by Josh White for Sharecast.com.